Approval · Notice of Compliance 27711 · 2022
CREDELIO PLUS: Notice of Compliance 27711
Issued March 4, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27711
- Date
- March 4, 2022
- Company
- Elanco Canada LimitedGuelph, Ontario, Canada
- Product type
- Veterinary
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CREDELIO PLUS | 02525674 | Marketed |
| CREDELIO PLUS | 02525682 | Marketed |
| CREDELIO PLUS | 02525690 | Marketed |
| CREDELIO PLUS | 02525704 | Marketed |
| CREDELIO PLUS | 02525712 | Marketed |
Medicinal ingredients
- MILBEMYCIN OXIME 2.11 MG per TAB
- LOTILANER 56.25 MG per TAB
- MILBEMYCIN OXIME 4.22 MG per TAB
- LOTILANER 112.5 MG per TAB
- MILBEMYCIN OXIME 8.44 MG per TAB
- LOTILANER 225 MG per TAB
- MILBEMYCIN OXIME 16.88 MG per TAB
- LOTILANER 450 MG per TAB
- MILBEMYCIN OXIME 33.75 MG per TAB
- LOTILANER 900 MG per TAB